By Fineline Cube Zhongsheng Pharmaceutical (SHE: 002317) announced that it has submitted a clinical trial application in China for a new indication of onradivir, its self‑developed Category 1 innovative drug, for the treatment of influenza A in patients at high risk of complications. The filing extends the clinical footprint of onradivir — the world’s first influenza RNA polymerase PB2 protein inhibitor, approved in China in May 2025 — beyond uncomplicated disease into a higher‑acuity population where antiviral efficacy carries the greatest medical value.
Regulatory & Label Expansion Timeline
| Item | Status | Detail |
|---|---|---|
| New indication trial application | Submitted (Sept 2, 2026) | Onradivir for influenza A in patients at high risk of complications |
| Uncomplicated influenza A in adults | Approved (May 2025) | First approved indication in China |
| Adolescents aged 12–17 (uncomplicated influenza A) | Supplemental application accepted by NMPA | Onradivir tablets |
| Onradivir granules | Marketing application accepted; priority review granted by NMPA | New formulation for broader patient access |
Drug Profile & Mechanism of Action
- Molecule: Onradivir, a self‑developed Category 1 innovative drug from Zhongsheng Pharmaceutical
- Target / Class: World’s first influenza RNA polymerase PB2 protein inhibitor
- Innovation: Distinct mechanism of action compared with existing neuraminidase inhibitors and cap‑dependent endonuclease inhibitors, with global independent intellectual property rights
- Current Indication: Treatment of uncomplicated influenza A in adult patients (approved in China, May 2025)
Market Impact & Outlook
- High‑risk expansion: Moving onradivir into patients at high risk of complications targets the population where antiviral treatment delivers the greatest clinical benefit — and where physicians most actively prescribe
- Multi‑front label build: With the adolescent supplemental application accepted and the granules formulation under priority review, Zhongsheng Pharmaceutical is simultaneously broadening onradivir’s age range and formulation flexibility
- First‑in‑class moat: As the world’s first PB2 inhibitor with global independent IP, onradivir holds differentiated positioning in a market dominated by older‑mechanism antivirals
- Lifecycle strategy: The sequential indication, population, and formulation expansions form a classic lifecycle management playbook that can support sustained uptake of onradivir across influenza seasons in China
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the clinical trial application, regulatory review outcomes, and commercial potential of onradivir across its indications and formulations. Actual results may differ materially due to clinical, regulatory, competitive, and market risks. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech